Tenofovir Alafenamide Fumarate

富马酸磷丙替诺福韦

Report date: 2022/12/07 17:52:48
NME

Base Information

Drug NameTenofovir Alafenamide Fumarate
Drug Alias Nametenofovirum alafenamidum富马酸替诺福韦艾拉酚胺tenofovir alafenamida替诺福韦阿拉芬胺Tenofovir Alafenamide +[14] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsFatigueMultiple Sclerosis, Relapsing-RemittingHepatitis C, Chronic +[8] 
Global Approved IndicationsHepatitis B, ChronicHepatitis B
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritoryUnited States
Original Approved Date2016/11/10
Country/TerritoryBelgiumBulgariaCanada +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesHumanis Saglık Anonim SirketiGilead Sciences IncGilead Sciences Ireland Uc +[6] 
Inactive CompaniesJanssen R&D IrelandThomas Jefferson UniversityUniversity Of North Carolina At Chapel Hill +[4] 
Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsFatigueMultiple Sclerosis, Relapsing-RemittingHepatitis C, Chronic +[6] 

Other Information

ATC CodeJ05AF13
Related LinksWikipediaDrugBankKEGG